Evidence map›Paper›PMID 40760064›Full record

Observational studyScientific reports2025

Current clinical profiles for Chinese hemodialysis patients.

Xinju Zhao, Chengqian Ma, Liangying Gan, Fan Fan Hou, Xinling Liang, Xiaonong Chen, Zhaohui Ni, Yuqing Chen, Xue Li, Wudong Guo and 1 more

Abstract readObservational Study
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xinju Zhao *Department of Nephrology, Peking University People's Hospital, Unit 10C in Ward Building, 11 Xizhimennan Street, Xicheng District, Beijing, 100044, China.
Chengqian Ma *Department of Nephrology, Peking University People's Hospital, Unit 10C in Ward Building, 11 Xizhimennan Street, Xicheng District, Beijing, 100044, China.
Liangying GanDepartment of Nephrology, Peking University People's Hospital, Unit 10C in Ward Building, 11 Xizhimennan Street, Xicheng District, Beijing, 100044, China.
Fan Fan HouDivision of Nephrology, Nanfang Hospital, National Clinical Research Center of Kidney Disease, State Key Laboratory of Organ Failure Research, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, China.
Xinling LiangDivision of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Xiaonong ChenDivision of Nephrology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Zhaohui NiDepartment of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yuqing ChenRenal Division, Peking University First Hospital, Beijing, China. cyq@bjmu.edu.cn.
Xue LiDivision of Health Technology Assessment, National Health Development Research Center, Beijing, China.
Wudong GuoDivision of Health Technology Assessment, National Health Development Research Center, Beijing, China.
Li ZuoDepartment of Nephrology, Peking University People's Hospital, Unit 10C in Ward Building, 11 Xizhimennan Street, Xicheng District, Beijing, 100044, China. zuoli@bjmu.edu.cn.

Funding

Natural Science Foundation of Beijing Municipality No.7222201Research Project of Blood Purification Center Branch of Chinese Hospital Association No. CHABP2021-11
6 · The paper itself

Abstract

The prevalence of hemodialysis (HD) patients in China is escalating, necessitating a comprehensive understanding of their clinical profiles. This study offers an in-depth analysis of the baseline data from the China Dialysis Outcomes and Practice Patterns Study (DOPPS) Phase 7 (DOPPS7), aiming to assess the current clinical characteristics and target ranges for the most recent years. It also compares these findings with those from DOPPS Phase 5. The DOPPS is a well-regarded international, prospective, and observational cohort study. Our analysis focused on the initial sample of patients enrolled in China DOPPS7. We report the demographic and clinical characteristics of 1843 patients, with a mean age of 61 ± 14 years and a male predominance (60.7%). The median dialysis vintage was 2.64 years, with diabetes (31.7%) and chronic glomerulonephritis (21.4%) being the leading causes of end-stage kidney disease (ESKD). Notably, 81.2% of patients had a single-pooled Kt/V ≥ 1.2, and 80.5% maintained albumin levels > 3.5 g/dl. Hemoglobin levels within the target range (110-130 g/dl) were observed in 44.2% of patients, while serum calcium (8.4-10.2 mg/dl) and phosphate (3.5-5.5 mg/dl) were within target ranges in 63.8% and 38.3% of patients, respectively. PTH levels were maintained within 150-600 pg/dl in 57.6% of patients, and 84.7% utilized fistula as their vascular access. Significant variations were noted in demographic, clinical, laboratory, and treatment characteristics among the three cities involved in the study. Compared to DOPPS5, improvements were observed in the proportion of patients meeting standards for hemoglobin, blood phosphorus, iPTH, and spKTV, while serum calcium, TSAT, and ferritin levels remained relatively stable. However, an increase in the proportion of patients with albumin < 3.5 g/dl was noted. The study's limitations include the exclusion of patients from smaller cities and remote areas, where HD patient conditions might differ significantly from those reported.

Indexed as

Kidney Failure, ChronicRenal DialysisAdultAgedCalciumChinaEast Asian PeopleFemaleHemoglobinsHumansMaleMiddle AgedProspective StudiesCalciumHemoglobinsAnemiaCKD-MBDDOPPSEnd-stage kidney diseaseHemodialysis

Identifiers

PMID40760064
PMCPMC12322052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.